The legal cannabis sector in Australia is evolving rapidly, driven by shifting public attitudes, medical advancements, and evolving state-level policies. While recreational cannabis remains illegal under federal law, several states have introduced regulated medical cannabis programs, creating a fragmented but expanding market. Recent data from the Australian Bureau of Statistics (ABS) shows that over 1.5 million Australians used cannabis in 2022, with medical use accounting for a growing share of demand—particularly among patients seeking alternatives to prescription opioids.

The State of Medical Cannabis Licensing

Australia’s medical cannabis industry operates under strict licensing frameworks, with each state managing its own approval processes. For example, New South Wales (NSW) has one of the most advanced systems, allowing licensed medical practitioners to prescribe cannabis-based products for conditions like chronic pain, epilepsy, and multiple sclerosis. The Therapeutic Goods Administration (TGA) regulates all medical cannabis products, ensuring they meet strict quality and safety standards. However, the process of obtaining a medical cannabis licence can be lengthy and costly, with some patients waiting months for approval, particularly in states with tighter regulations like Victoria.

The most notable recent development is the expansion of licensed cultivation and distribution networks. In Queensland, the state government has partnered with private companies to establish dedicated medical cannabis farms, while Tasmania has seen a surge in small-scale growers after its 2021 legalisation of medical cannabis. The economic impact is still emerging, but projections suggest the sector could generate over $1 billion annually by 2025, driven by both medical and emerging recreational markets in states like Western Australia.

• Over 1.5 million Australians used cannabis in 2022, with medical use rising by 30% since 2019.
• Victoria has the highest number of medical cannabis prescriptions, with over 50,000 approved annually.
• Tasmania’s medical cannabis industry was fully operationalised in 2021, allowing licensed growers to supply state-wide.
• The Therapeutic Goods Administration (TGA) approves only 12 cannabis-based medicinal products, all of which are derived from low-THC varieties.
• Recreational cannabis is decriminalised in NSW and Queensland, but not federally legalised.

Challenges and Future Outlook

The biggest hurdle remains public perception, with many Australians still wary of cannabis due to lingering stigma. Advocacy groups like the Australian Medical Cannabis Association (AMCA) are pushing for broader reforms, including federal legalisation of medical cannabis and clearer guidelines on recreational use. The COVID-19 pandemic temporarily disrupted supply chains, but recent infrastructure investments—such as the Australian Cannabis Industry Association’s (ACIA) new training programs—are expected to stabilise production by 2024.

Looking ahead, the market is likely to expand further with potential for recreational legalisation in states like South Australia and Western Australia. However, regulatory inconsistencies between jurisdictions could create operational challenges for growers and distributors. The TGA’s recent approval of new cannabis-based treatments for PTSD and anxiety reflects a growing acceptance of medical cannabis as a legitimate treatment option, but political will remains a critical factor in shaping Australia’s cannabis future.

Key Players and Market Trends

Major players in Australia’s medical cannabis sector include companies like Canopy Growth Australia, which operates licensed cultivation facilities in Queensland, and Australian Cannabis Industries (ACI), which supplies products to hospitals and private clinics. Emerging startups are focusing on niche markets, such as CBD-derived products for anxiety and sleep disorders. The industry’s growth is also being supported by increased funding from state governments, with NSW allocating $10 million to research and development in 2023.

One of the most interesting trends is the rise of “cannabis-friendly” pharmacies, where patients can access medical cannabis products alongside traditional medications. For example, in Sydney, the Pharmacy Guild has partnered with medical cannabis suppliers to create dedicated consultation rooms, helping to normalise the treatment process. However, concerns remain about access equity, with rural communities often facing longer wait times for deliveries.

See details